Comprehensive toxicity profile of the 4AC-4THP neoadjuvant regimen in HER2-positive breast cancer: a multicenter real-world study in Vietnam
{{output}}
Background: The 4AC-4THP regimen-comprising doxorubicin and cyclophosphamide followed by docetaxel, trastuzumab, and pertuzumab-has been widely adopted as neoadjuvant treatment for HER2-positive breast cancer. While efficacy data... ...
